A Fast and Low-Cost Approach for Binding Mode Validation of AI-Designed Therapeutics
This paper introduces HDX FineMapping, a fast, low-cost, and high-resolution mass spectrometry methodology that achieves 100% sequence coverage and complete epitope characterization for glycosylated targets like PD1, offering a superior alternative to traditional methods for validating AI-designed therapeutics without requiring crystallization or mutations.